Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial
Bruce D. Cheson, Nancy L. Bartlett, Betsy LaPlant, Hun J. Lee, Ranjana J. Advani, Beth Christian, Catherine S. Diefenbach, Tatyana A. Feldman, Stephen M. Ansell
Dive into the research topics of 'Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial'. Together they form a unique fingerprint.